Clinical Trials - Gastrointestinal

Colorectal

STEAM (Sequencing Triplet with Avastin and Maintenance):
FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) VS. FOLFOX/ Bevacizumab in First-Line Metastatic Colorectal Cancer (Genentech ML28442)

 II

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

 Nebraska Methodist Hospital
Omaha

 Colorectal

 A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients with First Line Metastatic Colorectal Cancer (mCRC) (Sara Cannon GI 154)

 II

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

 Nebraska Methodist Hospital
Omaha

 Colorectal

A Phase III Trial of Six (6) Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CALGB C80702)

 III

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

--------------------- 

Deborah Meyer, RN, BGS

 (402) 559-6941 dmeyerk@unmc.edu  or Jolene Tijerina

------------------------

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

-----------------------

Good Samaritan – Michaela Sherbeck michaelasherbeck@catholichealth.net

--------------------

CHI  -- JoAnn Wilde 402-717-4714, joann.wilde@alegent.org

---------------------------

Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

 

 Nebraska Methodist Hospital
Omaha ; Nebraska Medical Center, Omaha, NE; Missouri Valley Cancer Consortium, Omaha, NE;  Good Samaritan Cancer Center, Kearney, NE;  Saint Francis Cancer Treatment Center, Grand Island, NE;  Nebraska Cancer Research Center, Lincoln NE; CHI.

 GIST

 A Phase II Study of the Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor (GIST)  (Sara Cannon GI 148)

 II

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

 Nebraska Methodist Hospital
Omaha

 Colorectal

Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer (USOR 12091)

 III

 Faye Park, fpark@nebraskacancer.com, 402-691-6972  ------------------

Deborah Meyer, RN, BGS    (402) 559-6941 dmeyerk@unmc.edu  or Jolene Tijerina

------------------------

 Nebraska Cancer Specialists, Omaha; Nebraska Medical Center, Omaha, NE;  

 Colorectal

 Polyp Prevention Trial in Patients with Resected Colon Cancer (P5)

 

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

---------------------- 

Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

----------------------------

Good Samaritan – Michaela Sherbeck michaelasherbeck@catholichealth.net

-------------------------------

Saint Francis  - Rebecca Hadenfeldt - RHadenfeldt@sfmc-gi.org

--------------------------------

 Missouri Valley Cancer Consortium, Omaha, NE; Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE; Good Samaritan Cancer Center, Kearney, NE; Saint Francis Cancer Treatment Center, Grand Island, NE. 

 Colorectal

 A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic
Antibody, Ramucirumab, in Advanced, K-RAS Wild-type Colorectal Cancer Following Progression on
Bevacizumab-Containing Chemotherapy (E7208) Suspended
6/14/12 for AE
review

 II

 Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

------------------------------

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

 Nebraska Cancer Research Center/ Lincoln Medical Education Partnership Lincoln, NE; Missouri Valley Cancer Consortium, Omaha, NE

 

Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses

versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with

Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

 

 Faye Park, fpark@nebraskacancer.com, 402-691-6972

 Nebraska Cancer Specialists, Omaha, NE

 

 

A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

 

 Faye Park, fpark@nebraskacancer.com, 402-691-6972

 Nebraska Cancer Specialists, Omaha, NE

  Colorectal

 A phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer (USOR 12091)

 III

 Faye Park, fpark@nebraskacancer.com, 402-691-6972

 Nebraska Cancer Specialists, Omaha, NE

 Colorectal

A double blind placebo-controlled trial of eflomithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with Stage 0-III colon cancer, Phase III (SWOG-S0820)

 III

 Good Samaritan – Michaela Sherbeck - michaelasherbeck@catholichealth.net

 Good Samaritan Cancer Center, Kearney, NE.

 

HOG GI12-162:  A Randomized  Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab with or without Irinotecan as Second Line Therapy in Patients with Metastatic Colorectal Cancer (NU 0714)

 

 

Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129

 

Nebraska Methodist Hospital

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software